📊 CAI Key Takeaways
Is Caris Life Sciences, Inc. (CAI) a Good Investment?
Caris Life Sciences demonstrates exceptional 97% revenue growth with positive free cash flow generation ($22.5M) and a substantial cash balance ($819.9M), indicating strong market demand and financial runway. However, the company remains unprofitable at the net income level with concerning 0.4x interest coverage, requiring successful execution to achieve profitability and debt management.
Caris Life Sciences shows unusually strong top-line momentum, with revenue up 97.0% year over year and a swing to positive operating income and free cash flow, indicating improving scale economics. The balance sheet is also solid, with very high liquidity and a large cash position, but the company remains net unprofitable and interest coverage is still weak, so execution on sustained margin expansion remains critical.
Caris Life Sciences, Inc. Key Strengths (CAI)
- Exceptional 97% YoY revenue growth in medical laboratory services sector
- Positive free cash flow of $22.5M with 10.4% FCF margin indicates cash generation capability
- Strong liquidity position with $819.9M cash and 7.05x current ratio provides significant financial flexibility
- Net loss improving 87.3% YoY suggests trajectory toward profitability
- Operating cash flow positive at $32.9M despite growth-stage operations
- Revenue growth is exceptionally strong at 97.0% YoY, suggesting strong demand and scaling momentum
- Operating profitability and positive free cash flow indicate improving business quality and better cash conversion
- Balance sheet liquidity is strong, with $796.27M in cash and a 7.85x current ratio
CAI Stock Risks: Caris Life Sciences, Inc. Investment Risks
- Company remains unprofitable on net income basis (-$510K) with negative net margin of -0.2%
- Critical weakness: 0.4x interest coverage ratio indicates inability to comfortably service debt from operations
- Thin 2.4% operating margin requires continued revenue growth and margin expansion for sustainability
- High long-term debt of $381.1M represents 64% of equity, constraining financial flexibility
- Gross profit data unavailable; inability to assess service delivery margin quality and pricing power
- Net income remains negative, so full earnings profitability has not yet been achieved
- Interest coverage of 0.8x indicates debt servicing remains tight despite positive operating income
- Gross margin data is unavailable, limiting visibility into underlying unit economics and margin durability
Key Metrics to Watch
- Path to net profitability and sustained positive net income
- Interest coverage ratio improvement toward 1.5x+ to ensure debt service comfort
- Gross margin trend as company scales (need for transparency on cost structure)
- Operating margin expansion toward industry benchmarks
- Free cash flow sustainability and conversion rate of revenue growth to cash generation
- Net margin and sustained GAAP net income improvement
- Interest coverage and debt service capacity
Caris Life Sciences, Inc. (CAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.05x current ratio provides a solid financial cushion.
CAI Profit Margin, ROE & Profitability Analysis
CAI vs Healthcare Sector: How Caris Life Sciences, Inc. Compares
How Caris Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Caris Life Sciences, Inc. Stock Overvalued? CAI Valuation Analysis 2026
Based on fundamental analysis, Caris Life Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Caris Life Sciences, Inc. Balance Sheet: CAI Debt, Cash & Liquidity
CAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Caris Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-13.24 indicates the company is currently unprofitable.
CAI Revenue Growth, EPS Growth & YoY Performance
CAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $120.9M | -$510.0K | $0.00 |
| Q3 2025 | $101.6M | $24.3M | $0.08 |
| Q2 2025 | $100.0M | -$66.2M | $-2.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Caris Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
CAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Caris Life Sciences, Inc. (CIK: 0002019410)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CAI
What is the AI rating for CAI?
Caris Life Sciences, Inc. (CAI) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CAI's key strengths?
Claude: Exceptional 97% YoY revenue growth in medical laboratory services sector. Positive free cash flow of $22.5M with 10.4% FCF margin indicates cash generation capability. ChatGPT: Revenue growth is exceptionally strong at 97.0% YoY, suggesting strong demand and scaling momentum. Operating profitability and positive free cash flow indicate improving business quality and better cash conversion.
What are the risks of investing in CAI?
Claude: Company remains unprofitable on net income basis (-$510K) with negative net margin of -0.2%. Critical weakness: 0.4x interest coverage ratio indicates inability to comfortably service debt from operations. ChatGPT: Net income remains negative, so full earnings profitability has not yet been achieved. Interest coverage of 0.8x indicates debt servicing remains tight despite positive operating income.
What is CAI's revenue and growth?
Caris Life Sciences, Inc. reported revenue of $216.2M.
Does CAI pay dividends?
Caris Life Sciences, Inc. does not currently pay dividends.
Where can I find CAI SEC filings?
Official SEC filings for Caris Life Sciences, Inc. (CIK: 0002019410) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CAI's EPS?
Caris Life Sciences, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CAI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Caris Life Sciences, Inc. has a A grade with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CAI stock overvalued or undervalued?
Valuation metrics for CAI: ROE of -0.1% (sector avg: 15%), net margin of -0.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CAI's AI grade for 2026?
Our dual AI analysis gives Caris Life Sciences, Inc. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CAI's free cash flow?
Caris Life Sciences, Inc.'s operating cash flow is $32.9M, with capital expenditures of $10.3M. FCF margin is 10.4%.
How does CAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -0.2% (avg: 12%), ROE -0.1% (avg: 15%), current ratio 7.05 (avg: 2).